Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNNMedical - Instruments & Supplies
+$0.37 today
- Market cap
- $158.01M
- Beta
- 4.34
- P/E (TTM)
- 99.1
- EPS (TTM)
- $0.16
Volume 0.09M
Average 0.03M
NNNN Property, Plant & Equipment (Net)
Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.
Anbio Biotechnology Class A Ordinary SharesNASDAQ: NNNN
Property, Plant & Equipment (Net) · Q4 FY2025 · quarter ended Dec 2025
Property, plant & equipment (net) remains negative
Q4 FY2025 property, plant & equipment (net) was $0, compared with $0 a year earlier.
Context
- Property, plant & equipment (net) amounted to 0.0% of total assets at the end of Q4 FY2025, unchanged from a year earlier.
- Property, plant & equipment (net) increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Property, Plant & Equipment (Net) history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Property, Plant & Equipment (Net) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 12.06K | — |
| FY2021 | 2021-12-31 | 0 | — |
Property, Plant & Equipment (Net) vs competitors
How NNNN compares with its peers on the latest reported figures
- Peers report in different currencies, so property, plant & equipment (net) is compared through growth and share of total assets rather than absolute size.
- Property, plant & equipment (net) amounts to 0.0% of total assets for NNNN, versus a peer median of 12.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $8.09B USD | +50.8% | -5.7% | 61.4% | |
| Mar 2026 | CA$286.05M CAD | +6.2% | +1.5% | 21.8% | |
| Mar 2026 | $150.5M USD | +6.1% | -1.2% | 14.3% | |
| Feb 2026 | $29.14M USD | -10.4% | -10.5% | 11.2% | |
| Mar 2026 | $18M USD | +124.6% | +185.7% | 13.2% | |
| Mar 2026 | $16M USD | +211.1% | +59.9% | 17.1% | |
| Dec 2025 | $12.86M USD | — | — | 3.8% | |
| Mar 2026 | $3.97M USD | -17.5% | -24.9% | 3.1% | |
| Mar 2026 | $2.86M USD | +95.6% | +9.3% | 0.5% | |
| Mar 2026 | $785K USD | -43.2% | -30.9% | 0.2% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | Dec 2025 | $0 USD | — | — | 0.0% |
| Peer median (excluding NNNN) | — | +6.2% | -1.2% | 12.2% | |
Competitors are the stored peer set for NNNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
Intrinsic Alpha fair value
Locked
Current Price
$3.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.